Ann Tomlin Appointed as Chief Human Resources Officer at Lyell Immunopharma

South San Francisco, California, United States, March 2025 – Ann Tomlin has been named Chief Human Resources Officer (CHRO) at Lyell Immunopharma. In her new role, she will lead the HR/People Team, supporting an innovative and courageous organization focused on advancing a diverse pipeline of cell therapies for patients with hematologic malignancies and solid tumors.

Denise Namakando Appointed as Managing Director UK&I at Dote

Amy Coleman Named EVP and Chief People Officer at Microsoft

Kathleen Hogan Appointed as EVP, Office of Strategy and Transformation at Microsoft

Prior to this role, Ann Tomlin served as Senior Vice President of Human Resources at Lyell Immunopharma for nearly two years, playing a crucial role in developing people strategies and organizational effectiveness to support the company’s clinical-stage pipeline.

**Register Your organization for HPTW Certification (Singapore Trademark)**

Before joining Lyell, she was Senior Vice President of Human Resources at Myovant Sciences, where she led HR through a period of high growth, supporting the company’s mission to redefine care for women and men through innovative therapies.

Previously, Ann spent over five years at AbbVie, first as Head of Human Resources for the AbbVie Bay Area, where she helped build the company’s new oncology-focused organization, and earlier as Head of Human Resources at Pharmacyclics, an AbbVie Company, where she supported cancer research and development initiatives.

Her tenure at AbbVie and its subsidiary Pharmacyclics was preceded by nearly two decades at Abbott Laboratories, where she held various leadership roles in global talent management, HR strategy, manufacturing operations, and commercial HR functions.

In addition to her corporate roles, Ann co-founded the Biotech CHRO Sisterhood, an organization fostering collaboration among senior HR leaders in the biotech sector.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation CAR T-cell therapies to treat solid tumors and hematologic malignancies. The company leverages novel T-cell reprogramming technology to generate durable and effective T-cell therapies, aiming to achieve consistent, long-lasting clinical responses. With a fully integrated approach to technology discovery, manufacturing, and clinical development, Lyell is dedicated to advancing innovative cell therapy solutions.